SCHEMBL5445672

SCHEMBL5445672

NC1CCN(S(=O)(=O)c2ccc(Nc3ncc(/C=C/c4cccc5[nH]ncc45)cn3)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.41
SYK P43405 1/20 0.38
CDK2 P24941 10/20 0.36
CCNE1 P24864 9/20 0.36
FLT3 P36888 9/20 0.36
USP2 O75604 3/20 0.36
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ABL1 P00519 1/20 0.36
SRC P12931 1/20 0.36
KIT P10721 1/20 0.36
AXL P30530 1/20 0.35
TYRO3 Q06418 1/20 0.35
MERTK Q12866 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
STAT3 P40763 1/20 0.35
MAPK10 P53779 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5445675 1.00 NAMPT (0.41) NAMPTSYKCDK2CCNE1FLT3
SCHEMBL5442216 0.89 IKBKB (0.44) NAMPTABL1SRC
SCHEMBL5442212 0.89 IKBKB (0.44) NAMPTABL1SRC
SCHEMBL5442125 0.88 PRKCQ (0.42) NAMPTSYKCDK2CCNE1FLT3
SCHEMBL5442129 0.88 PRKCQ (0.42) NAMPTSYKCDK2CCNE1FLT3
SCHEMBL5442204 0.86 CA12 (0.44) NAMPTABL1SRCCDK7CDK9
SCHEMBL5442201 0.86 CA12 (0.44) NAMPTABL1SRCCDK7CDK9
SCHEMBL5442272 0.81 NAMPT (0.41) NAMPTCDK2ABL1SRCCCNT1
SCHEMBL5442277 0.81 NAMPT (0.41) NAMPTCDK2ABL1SRCCCNT1
SCHEMBL5442243 0.80 NAMPT (0.39) NAMPTCDK2ABL1SRCCCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
WO-2007056075-A2 SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR NAMPT 2364/4885SYK 597/4885CDK2 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.